Cytokinetics' MYQORZO Receives FDA Approval for Enhanced Label Data on Obstructive Hypertrophic Cardiomyopathy Treatment
Rapid Read

Cytokinetics' MYQORZO Receives FDA Approval for Enhanced Label Data on Obstructive Hypertrophic Cardiomyopathy Treatment

What's Happening? Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for MYQORZO® (aficamten). This approval updates the drug's U.S. prescribing information to include data from the MAPLE-HCM Phase 3 trial. Th
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.